Literature DB >> 33578070

An ensemble learning based framework to estimate warfarin maintenance dose with cross-over variables exploration on incomplete data set.

Yan Liu1, Jihui Chen1, Yin You2, Ajing Xu1, Ping Li1, Yu Wang3, Jiaxing Sun3, Ze Yu3, Fei Gao4, Jian Zhang5.   

Abstract

MOTIVATION: Warfarin is a widely used oral anticoagulant, but it is challenging to select the optimal maintenance dose due to its narrow therapeutic window and complex individual factor relationships. In recent years, machine learning techniques have been widely applied for warfarin dose prediction. However, the model performance always meets the upper limit due to the ignoration of exploring the variable interactions sufficiently. More importantly, there is no efficient way to resolve missing values when predicting the optimal warfarin maintenance dose.
METHODS: Using an observational cohort from the Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, we propose a novel method for warfarin maintenance dose prediction, which is capable of assessing variable interactions and dealing with missing values naturally. Specifically, we examine single variables by univariate analysis initially, and only statistically significant variables are included. We then propose a novel feature engineering method on them to generate the cross-over variables automatically. Their impacts are evaluated by stepwise regression, and only the significant ones are selected. Lastly, we implement an ensemble learning based approach, LightGBM, to learn from incomplete data directly on the selected single and cross-over variables for dosing prediction.
RESULTS: 377 unique patients with eligible and time-independent 1173 warfarin order events are included in this study. Through the comprehensive experimental results in 5-fold cross-validation, our proposed method demonstrates the efficiency of exploring the variable interactions and modeling on incomplete data. The R2 can achieve 75.0% on average. Moreover, the subgroup analysis results reveal that our method performs much better than other baseline methods, especially in the medium-dose and high-dose subgroups. Lastly, the IWPC dosing prediction model is used for further comparison, and our approach outperforms it by a significant margin.
CONCLUSION: In summary, our proposed method is capable of exploring the variable interactions and learning from incomplete data directly for warfarin maintenance dose prediction, which has a great premise and is worthy of further research.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Dose prediction; Incomplete data; Machine learning; Warfarin

Year:  2021        PMID: 33578070     DOI: 10.1016/j.compbiomed.2021.104242

Source DB:  PubMed          Journal:  Comput Biol Med        ISSN: 0010-4825            Impact factor:   4.589


  4 in total

1.  Nonlinear Machine Learning in Warfarin Dose Prediction: Insights from Contemporary Modelling Studies.

Authors:  Fengying Zhang; Yan Liu; Weijie Ma; Shengming Zhao; Jin Chen; Zhichun Gu
Journal:  J Pers Med       Date:  2022-04-29

2.  A Prediction Model for Tacrolimus Daily Dose in Kidney Transplant Recipients With Machine Learning and Deep Learning Techniques.

Authors:  Qiwen Zhang; Xueke Tian; Guang Chen; Ze Yu; Xiaojian Zhang; Jingli Lu; Jinyuan Zhang; Peile Wang; Xin Hao; Yining Huang; Zeyuan Wang; Fei Gao; Jing Yang
Journal:  Front Med (Lausanne)       Date:  2022-05-27

3.  Predicting Lapatinib Dose Regimen Using Machine Learning and Deep Learning Techniques Based on a Real-World Study.

Authors:  Ze Yu; Xuan Ye; Hongyue Liu; Huan Li; Xin Hao; Jinyuan Zhang; Fang Kou; Zeyuan Wang; Hai Wei; Fei Gao; Qing Zhai
Journal:  Front Oncol       Date:  2022-06-03       Impact factor: 5.738

4.  Warfarin anticoagulation management during the COVID-19 pandemic: The role of internet clinic and machine learning.

Authors:  Meng-Fei Dai; Shu-Yue Li; Ji-Fan Zhang; Bao-Yan Wang; Lin Zhou; Feng Yu; Hang Xu; Wei-Hong Ge
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.